DE69840932D1 - Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen - Google Patents

Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen

Info

Publication number
DE69840932D1
DE69840932D1 DE69840932T DE69840932T DE69840932D1 DE 69840932 D1 DE69840932 D1 DE 69840932D1 DE 69840932 T DE69840932 T DE 69840932T DE 69840932 T DE69840932 T DE 69840932T DE 69840932 D1 DE69840932 D1 DE 69840932D1
Authority
DE
Germany
Prior art keywords
administration
compositions
cells
increasing
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840932T
Other languages
English (en)
Inventor
Heidrun Engler
Tattanahalli L Nagabhushan
Stephen Kenneth Youngster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of DE69840932D1 publication Critical patent/DE69840932D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DE69840932T 1997-07-08 1998-07-08 Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen Expired - Lifetime DE69840932D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use
PCT/US1998/014241 WO1999002191A1 (en) 1997-07-08 1998-07-08 Compositions and methods for enhancing delivery of therapeutic agents to cells

Publications (1)

Publication Number Publication Date
DE69840932D1 true DE69840932D1 (de) 2009-08-06

Family

ID=25394956

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69842133T Expired - Lifetime DE69842133D1 (de) 1997-07-08 1998-07-08 Zusammensetzungen und Kits zur Erhöhung der Abgabe von therapeutischen Mitteln an Zellen
DE69840932T Expired - Lifetime DE69840932D1 (de) 1997-07-08 1998-07-08 Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69842133T Expired - Lifetime DE69842133D1 (de) 1997-07-08 1998-07-08 Zusammensetzungen und Kits zur Erhöhung der Abgabe von therapeutischen Mitteln an Zellen

Country Status (21)

Country Link
US (3) US7002027B1 (de)
EP (2) EP2106807B1 (de)
JP (2) JP4460148B2 (de)
KR (1) KR100691572B1 (de)
AR (1) AR016312A1 (de)
AT (2) ATE497786T1 (de)
AU (1) AU774338B2 (de)
CA (1) CA2294709C (de)
CY (1) CY1109367T1 (de)
DE (2) DE69842133D1 (de)
DK (1) DK1011733T3 (de)
ES (2) ES2328094T3 (de)
HK (2) HK1028961A1 (de)
HU (1) HUP0002683A3 (de)
IL (1) IL133929A0 (de)
MY (1) MY138257A (de)
NZ (1) NZ502060A (de)
PT (1) PT1011733E (de)
TW (1) TW490306B (de)
WO (1) WO1999002191A1 (de)
ZA (1) ZA986003B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20050025742A1 (en) * 1996-01-08 2005-02-03 Canji, Inc. Methods and compositions for interferon therapy
JP2002511446A (ja) 1998-04-08 2002-04-16 セルテック・セラピューティクス・リミテッド 脂 質
PT1456377T (pt) * 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
ATE502654T1 (de) * 2003-12-10 2011-04-15 Canji Inc Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
CA2723440A1 (en) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines for therapy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2488210A4 (de) 2009-10-12 2014-04-30 Smith Holdings Llc Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
CA2112375A1 (en) 1991-06-28 1993-01-07 Elizabeth G. Nabel Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
EP0633943A4 (de) 1992-04-03 1997-05-02 Alexander T Young Gentherapy unter verwendung zielgerichteter viraler vektoren.
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JPH07109983A (ja) 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
KR100218140B1 (ko) 1993-10-15 1999-09-01 잭 제이 루치이스 치료학적 전달 조성물 및 그의 사용 방법
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
WO1997005209A1 (en) * 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US20050025742A1 (en) 1996-01-08 2005-02-03 Canji, Inc. Methods and compositions for interferon therapy
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6283940B1 (en) * 1997-08-29 2001-09-04 S. Grant Mulholland Catheter
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
PT1456377T (pt) 2001-12-20 2019-09-10 Merck Sharp & Dohme Composições de syn3 e processos
KR100499787B1 (ko) 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
CN100429220C (zh) 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
ATE502654T1 (de) 2003-12-10 2011-04-15 Canji Inc Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren

Also Published As

Publication number Publication date
MY138257A (en) 2009-05-29
EP1011733B1 (de) 2009-06-24
EP1011733A4 (de) 2004-09-29
AU8390198A (en) 1999-02-08
AR016312A1 (es) 2001-07-04
AU774338B2 (en) 2004-06-24
HK1134025A1 (en) 2010-04-16
US20100028431A1 (en) 2010-02-04
US8022044B2 (en) 2011-09-20
IL133929A0 (en) 2001-04-30
DE69842133D1 (de) 2011-03-24
WO1999002191A1 (en) 1999-01-21
KR20010021620A (ko) 2001-03-15
PT1011733E (pt) 2009-09-15
ES2328094T3 (es) 2009-11-06
ATE497786T1 (de) 2011-02-15
JP2001509492A (ja) 2001-07-24
US7538093B2 (en) 2009-05-26
DK1011733T3 (da) 2009-09-28
US7002027B1 (en) 2006-02-21
EP2106807B1 (de) 2011-02-09
US20060199782A1 (en) 2006-09-07
NZ502060A (en) 2003-01-31
JP2010070565A (ja) 2010-04-02
ATE434448T1 (de) 2009-07-15
EP1011733A1 (de) 2000-06-28
CA2294709A1 (en) 1999-01-21
CY1109367T1 (el) 2014-07-02
CA2294709C (en) 2010-05-11
HUP0002683A2 (hu) 2000-12-28
KR100691572B1 (ko) 2007-03-12
HUP0002683A3 (en) 2005-09-28
HK1028961A1 (en) 2001-03-16
ES2362027T3 (es) 2011-06-27
JP4460148B2 (ja) 2010-05-12
ZA986003B (en) 1999-01-28
TW490306B (en) 2002-06-11
EP2106807A1 (de) 2009-10-07

Similar Documents

Publication Publication Date Title
DE69840932D1 (de) Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen
ATE268597T1 (de) Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen
DE69927388D1 (de) Gerät zur verabreichung von medikamenten und genen in gewebe
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
ID26773A (id) Sulfur tersubstitusi pada asam sulfonilaminokarboksilat n-arilamida, persiapan, penggunaan dan persiapan pembuatan obat yang menyertainya
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
PT1032555E (pt) Aminoacidos ciclicos e derivados uteis como agentes farmaceuticos
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
ID28057A (id) Obat dalam bentuk pil lunak dan proses pembuatannya
HUP9902655A3 (en) Pharmaceutical composition of hedgehog proteins and use thereof
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE69906754T2 (de) Einbringung von rauchmodifizierenden mitteln in rauchartikeln
ID22053A (id) Turunan asam aminofosfonat dalam sediaan farmasi
DE69522188T2 (de) Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
DE4495520T1 (de) Verfahren und pharmazeutische Zusammensetzung zum zielgerichten Anwenden von Wirkstoffen
ATE308365T1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
DE69827137D1 (de) Aminoethylphenoxyessigsäure-derivate und medikamente zur schmerzlinderung und förderung der entfernung von konkrementen bei urolithiasis
HUP0003244A3 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
DE69314796D1 (de) Zusammensetzungen und verfahren zur kumulativen kapazitätserhöhung von festenaufladbaren elektrochemischen zellen
DE69930603D1 (de) Zusammensetzung zur Wiederherstellung und Stimulierung der Hautbarrierefunktion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition